Anti-angiogenic therapy in pediatric brain tumors: An effective strategy?

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 3, 2014, Pages 418-432

  Sie, Mariska ^a   den Dunnen, Wilfred F A ^b   Hoving, Eelco W ^b   de Bont, Eveline S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Anti angiogenic therapy; Clinical trials; Epidermal growth factor receptor; Pediatric brain tumors; Vascular endothelial growth factor (receptor)

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CILENGITIDE; CRIZOTINIB; CYCLOPHOSPHAMIDE; ERLOTINIB; ETOPOSIDE; FLUINDOSTATIN; GAMMA INTERFERON; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; LOMUSTINE; NIMOTUZUMAB; NIMUSTINE; RANIMUSTINE; SEMAXANIB; STEROID; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VINCRISTINE; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FENOFIBRATE; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLOOD BRAIN BARRIER; BLOOD VESSEL FUNCTION; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD VESSEL; BRAIN STEM TUMOR; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL PROTOCOL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; EMBRYO DEVELOPMENT; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EPENDYMOMA; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; HYPOTHALAMIC CHIASMATIC GLIOMA; INTRACELLULAR SIGNALING; MEDIATOR; MEDULLOBLASTOMA; METRONOMIC CHEMOTHERAPY; METRONOMIC DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATIENT MONITORING; PERINATAL PERIOD; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOCYTIC ASTROCYTOMA; PONTINE GLIOMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REVIEW; THERAPY RESISTANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLEEDING; TUMOR ESCAPE; TUMOR RESISTANCE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; ANGIOGENESIS; CANCER MORTALITY; CANCER SURGERY; CHILD; CHILDHOOD CANCER; CHOROID PLEXUS TUMOR; EMBRYONAL BRAIN TUMOR; MORBIDITY; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANGIOGENESIS; ANTI-ANGIOGENIC THERAPY; CLINICAL TRIALS; EPIDERMAL GROWTH FACTOR RECEPTOR; PEDIATRIC BRAIN TUMORS; VASCULAR ENDOTHELIAL GROWTH FACTOR (RECEPTOR);

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CHILD; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84893748702     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.09.005     Document Type: Review

References (143)

1. Dolecek T.A., Propp J.M., Stroup N.E., Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012, 14(Suppl. 5):v1-v49.
2. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. Classification of tumours of the central nervous system 2007, IARC, Lyon. 4th ed.
3. Sie M., de Bont E.S., Scherpen F.J., Hoving E.W., den Dunnen W.F. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma: is it much different from glioblastoma?. Neuropathol Appl Neurobiol 2010, 36:636-647.
4. Bartels U., Hawkins C., Jing M., et al. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg 2006, 104:314-320.
5. Pollack I.F., Finkelstein S.D., Woods J., et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002, 346:420-427.
6. Mueller S., Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics 2009, 6:570-586.
7. Hargrave D., Bartels U., Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006, 7:241-248.
8. Ross G.W., Rubinstein L.J. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 1989, 70:31-36.
9. Ellison D.W., Kocak M., Figarella-Branger D., et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011, 10. 7,5751-10-7.
10. McGuire C.S., Sainani K.L., Fisher P.G. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 2009, 52:65-69.
11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
12. Mito T., Konomi H., Houdou S., Takashima S. Immunohistochemical study of the vasculature in the developing brain. Pediatr Neurol 1991, 7:18-22.
13. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992, 114:521-532.
14. Ballabh P., Braun A., Nedergaard M. Anatomic analysis of blood vessels in germinal matrix, cerebral cortex, and white matter in developing infants. Pediatr Res 2004, 56:117-124.
15. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
16. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
17. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
18. Reynolds L.P., Killilea S.D., Redmer D.A. Angiogenesis in the female reproductive system. FASEB J 1992, 6:886-892.
19. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13:159-167.
20. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580.
21. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
22. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
23. Ramsauer M., Krause D., Dermietzel R. Angiogenesis of the blood-brain barrier in vitro and the function of cerebral pericytes. FASEB J 2002, 16:1274-1276.
24. Scholler K., Trinkl A., Klopotowski M., et al. Characterization of microvascular basal lamina damage and blood-brain barrier dysfunction following subarachnoid hemorrhage in rats. Brain Res 2007, 1142:237-246.
25. Ribatti D., Vacca A., Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999, 1:293-302.
26. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
27. Fagiani E., Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013, 328:18-26.
28. Fukumura D., Duda D.G., Munn L.L., Jain R.K. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010, 17:206-225.
29. Vajkoczy P., Menger M.D. Vascular microenvironment in gliomas. Cancer Treat Res 2004, 117:249-262.
30. Wagemakers M., Sie M., Hoving E.W., Molema G., de Bont E.S., den Dunnen W.F. Tumor vessel biology in pediatric intracranial ependymoma. J Neurosurg Pediatr 2010, 5:335-341.
31. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
32. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
33. Woolard J., Bevan H.S., Harper S.J., Bates D.O. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation 2009, 16:572-592.
34. Houck K.A., Leung D.W., Rowland A.M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26031-26037.
35. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326.
36. Kusters B., de Waal R.M., Wesseling P., et al. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res 2003, 63:5408-5413.
37. Sie M., den Dunnen W.F., Scherpen F.J., Hoving E.W., de Bont E.S. Overlapping VEGF-A isoform ratios in pilocytic astrocytoma and glioblastoma. Cell Oncol 2012, 35(Suppl. 1). Abstract PP78.
38. Tozer G.M., Akerman S., Cross N.A., et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 2008, 68:2301-2311.
39. Bates D.O., Cui T.G., Doughty J.M., et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002, 62:4123-4131.
40. Rennel E.S., Varey A.H., Churchill A.J., et al. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer 2009, 101:1183-1193.
41. Miller-Kasprzak E., Jagodzinski P.P. 5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells. Biomed Pharmacother 2008, 62:158-163.
42. Varey A.H., Rennel E.S., Qiu Y., et al. VEGF 165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008, 98:1366-1379.
43. Harper S.J., Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer 2008, 8:880-887.
44. Bates D.O., Catalano P.J., Symonds K.E., et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012, 18:6384-6391.
45. Catena R., Larzabal L., Larrayoz M., et al. VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Mol Cancer 2010, 9:320.
46. Harris S., Craze M., Newton J., et al. Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale. PLoS ONE 2012, 7:e35231.
47. Hiratsuka S., Nakao K., Nakamura K., Katsuki M., Maru Y., Shibuya M. Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice. Mol Cell Biol 2005, 25:346-354.
48. Staton C.A. Class 3 semaphorins and their receptors in physiological and pathological angiogenesis. Biochem Soc Trans 2011, 39:1565-1570.
49. Koga K., Todaka T., Morioka M., et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001, 61:6248-6254.
50. Daly C., Eichten A., Castanaro C., et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013, 73:108-118.
51. Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009, 29:2011-2022.
52. Davis S., Papadopoulos N., Aldrich T.H., et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 2003, 10:38-44.
53. Pietila R., Natynki M., Tammela T., et al. Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses. J Cell Sci 2012, 125:2212-2223.
54. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
55. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009, 8:235-253.
56. Knights V., Cook S.J. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010, 125:105-117.
57. Asahara T., Bauters C., Zheng L.P., et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92:II365-II371.
58. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
59. Pollack I.F., Hamilton R.L., James C.D., et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006, 105:418-424.
60. Khatua S., Peterson K.M., Brown K.M., et al. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 2003, 63:1865-1870.
61. Bredel M., Pollack I.F., Hamilton R.L., James C.D. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999, 5:1786-1792.
62. Gilbertson R.J., Hill D.A., Hernan R., et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003, 9:3620-3624.
63. Gilbertson R.J. ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist 2005, 10:508-517.
64. Calzolari F., Malatesta P. Recent insights into PDGF-induced gliomagenesis. Brain Pathol 2010, 20:527-538.
65. Becher O.J., Hambardzumyan D., Walker T.R., et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 2010, 70:2548-2557.
66. Thorarinsdottir H.K., Santi M., McCarter R., et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res 2008, 14:3386-3394.
67. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
68. Seet R.C., Rabinstein A.A. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2012, 105:69-75.
69. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
70. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13:3942-3950.
71. Wildiers H., Guetens G., De Boeck G., et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003, 88:1979-1986.
72. Franco M., Man S., Chen L., et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006, 66:3639-3648.
73. Sikkema A.H., de Bont E.S., Molema G., et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol 2011, 37:538-548.
74. Gaur P., Bose D., Samuel S., Ellis L.M. Targeting tumor angiogenesis. Semin Oncol 2009, 36:S12-S19.
75. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
76. Norden A.D., Drappatz J., Wen P.Y. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009, 5:610-620.
77. Sennino B., McDonald D.M. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012, 12:699-709.
78. Thompson E.M., Frenkel E.P., Neuwelt E.A. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011, 76:87-93.
79. Ma J., Li S., Reed K., Guo P., Gallo J.M. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 2003, 305:833-839.
80. Ma J., Pulfer S., Li S., Chu J., Reed K., Gallo J.M. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001, 61:5491-5498.
81. Grossman R., Rudek M.A., Brastianos H., et al. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother Pharmacol 2012, 70:129-139.
82. Grossman R., Tyler B., Rudek M.A., et al. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. Cancer Chemother Pharmacol 2013, 72:93-100.
83. Zhou Q., Gallo J.M. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 2009, 11:301-310.
84. Arao T., Matsumoto K., Furuta K., et al. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells. Anticancer Res 2011, 31:2787-2796.
85. Arrondeau J., Mir O., Boudou-Rouquette P., et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 2012, 30:2046-2049.
86. Gotink K.J., Broxterman H.J., Labots M., et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011, 17:7337-7346.
87. Sitohy B., Nagy J.A., Jaminet S.C., Dvorak H.F. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 2011, 71:7021-7028.
88. Thurston G., Noguera-Troise I., Yancopoulos G.D. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 2007, 7:327-331.
89. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
90. Singh R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., Fidler I.J. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995, 92:4562-4566.
91. Beatty G., Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001, 166:2276-2282.
92. Samuel D.P., Wen P.Y., Kieran M.W. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs 2009, 18:973-983.
93. Allen J., Packer R., Bleyer A., Zeltzer P., Prados M., Nirenberg A. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors. J Clin Oncol 1991, 9:783-788.
94. Warren K., Bent R., Wolters P.L., et al. A phase 2 study of pegylated interferon alpha-2b (PEG-Intron((R))) in children with diffuse intrinsic pontine glioma. Cancer 2012, 118:3607-3613.
95. Wolff J.E., Wagner S., Reinert C., et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 2006, 79:315-321.
96. Packer R.J., Prados M., Phillips P., et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study. Cancer 1996, 77:2150-2156.
97. Wakabayashi T., Yoshida J., Mizuno M., Kito A., Sugita K. Effectiveness of interferon-beta, ACNU, and radiation therapy in pediatric patients with brainstem glioma. Neurol Med Chir (Tokyo) 1992, 32:942-946.
98. Ohno M., Natsume A., Fujii M., Ito M., Wakabayashi T. Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma. Pediatr Blood Cancer 2009, 53:37-41.
99. Kieran M.W., Turner C.D., Rubin J.B., et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005, 27:573-581.
100. Sterba J., Pavelka Z., Andre N., et al. Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatr Blood Cancer 2010, 54:616-617.
101. Padovani L., Andre N., Gentet J.C., et al. Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?. J Pediatr Hematol Oncol 2011, 33:600-604.
102. Minturn J.E., Janss A.J., Fisher P.G., et al. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer 2011, 56:39-44.
103. Peyrl A., Chocholous M., Kieran M.W., et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2012, 59:511-517.
104. Kim C.Y., Kim S.K., Phi J.H., et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neurooncol 2010, 100:193-198.
105. Lopez-Aguilar E., Sepulveda-Vildosola A.C., Betanzos-Cabrera Y., et al. Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children. Arch Med Res 2008, 39:655-662.
106. Turner C.D., Chi S., Marcus K.J., et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol 2007, 82:95-101.
107. Warren K.E., Goldman S., Pollack I.F., et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 2011, 29:324-329.
108. Hwang E.I., Jakacki R.I., Fisher M.J., et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2013, 60:776-782.
109. Aguilera D.G., Goldman S., Fangusaro J. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. Pediatr Blood Cancer 2011, 56:491-494.
110. Gururangan S., Chi S.N., Young Poussaint T., et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010, 28:3069-3075.
111. Narayana A., Kunnakkat S., Chacko-Mathew J., et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol 2010, 12:985-990.
112. Parekh C., Jubran R., Erdreich-Epstein A., et al. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol 2011, 103:673-680.
113. Gururangan S., Fangusaro J., Young Poussaint T., et al. Lack of efficacy of bevacizumab+irinotecan in cases of pediatric recurrent ependymoma-a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012, 14:1404-1412.
114. Reismuller B., Azizi A.A., Peyrl A., et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer 2010, 54:681-686.
115. Kieran M.W., Supko J.G., Wallace D., et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 2009, 52:169-176.
116. Broniscer A., Baker J.N., Tagen M., et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010, 28:4762-4768.
117. Bode U., Massimino M., Bach F., et al. Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther 2012, 12:1649-1659.
118. Saurez G., Cabanas R., Zaldivar M., et al. Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev 2009, 11:27-33.
119. Pollack I.F., Stewart C.F., Kocak M., et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 2011, 13:290-297.
120. Jakacki R.I., Hamilton M., Gilbertson R.J., et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium study. J Clin Oncol 2008, 26:4921-4927.
121. Broniscer A., Baker S.J., Stewart C.F., et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 2009, 15:701-707.
122. Geoerger B., Hargrave D., Thomas F., et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 2011, 13:109-118.
123. White-Koning M., Civade E., Geoerger B., et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res 2011, 17:4862-4871.
124. Geyer J.R., Stewart C.F., Kocak M., et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer 2010, 46:3287-3293.
125. Peyrl A., Azizi A., Czech T., et al. Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. Pediatr Blood Cancer 2009, 52:476-480.
126. Pollack I.F., Jakacki R.I., Blaney S.M., et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 2007, 9:145-160.
127. Baruchel S., Sharp J.R., Bartels U., et al. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer 2009, 45:2352-2359.
128. MacDonald T.J., Stewart C.F., Kocak M., et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium study PBTC-012. J Clin Oncol 2008, 26:919-924.
129. Sikkema A.H., Diks S.H., den Dunnen W.F., et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res 2009, 69:5987-5995.
130. van den Bent M.J., Vogelbaum M.A., Wen P.Y., Macdonald D.R., Chang S.M. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009, 27:2905-2908.
131. Brandes A.A., Franceschi E., Gorlia T., et al. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 2012, 48:896-903.
132. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
133. Gallego Perez-Larraya J., Lahutte M., Petrirena G., et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST+F criteria. Neuro Oncol 2012, 14:667-673.
134. Watling C.J., Lee D.H., Macdonald D.R., Cairncross J.G. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994, 12:1886-1889.
135. Henegar M.M., Moran C.J., Silbergeld D.L. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 1996, 84:174-179.
136. Kumar A.J., Leeds N.E., Fuller G.N., et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000, 217:377-384.
137. Ulmer S., Braga T.A., Barker F.G., Lev M.H., Gonzalez R.G., Gonzalez R.G. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006, 67:1668-1670.
138. Pichler J., Pachinger C., Pelz M., Kleiser R. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression-a pilot study. Eur J Radiol 2013, 82:e240-e245.
139. Warren K.E., Poussaint T.Y., Vezina G., et al. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer 2013, 60:1397-1401.
140. Wolff J.E., Brown R.E., Buryanek J., Pfister S., Vats T.S., Rytting M.E. Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatr Blood Cancer 2012, 59:27-33.
141. Trippett T.M., Herzog C., Whitlock J.A., et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. J Clin Oncol 2009, 27:5102-5108.
142. Fouladi M., Stewart C.F., Blaney S.M., et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010, 28:4221-4227.
143. McLaughlin M.E., Robson C.D., Kieran M.W., Jacks T., Pomeroy S.L., Cameron S. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol 2003, 25:644-648.